GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancer
GSK has secured a US accelerated approval for its oral lung cancer drug neladalkib, one of two assets at the heart of its $10.6 billion purchase of oncology drugmaker Nuvalent earlier this ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics statnews.com
- Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback scmp.com
- FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting endpoints.news
- Summit shares fall as FDA rejects closely watched PD-1/VEGF drug biopharmadive.com
- FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector ft.com
- FDA declines approval of Summit’s lung cancer treatment seekingalpha.com